Emergent BioSolutions Inc. announced a maximum three-year agreement valued at approximately $65 million to supply the Ontario Ministry of Health with NARCAN Nasal Spray. This contract is for the Ontario Naloxone Program (ONP), which Emergent has supported since 2018.
NARCAN Nasal Spray is designed to reverse the effects of an opioid poisoning and is the only 4 mg, intranasal naloxone spray in Canada with a four-year shelf life. The agreement ensures continued access to this life-saving medication across the province, distributed to individuals at risk and their communities.
This announcement follows Health Canada's recent approval of KLOXXADO Nasal Spray 8 mg, further bolstering Emergent's offerings in Canada to combat the opioid epidemic. Data from January through March 2025 showed a promising 30 percent decrease in overdose deaths in Ontario compared to the same period last year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.